SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, ...
A 36-year-old man with a diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), was referred to a psychiatry clinic for severe, ...
Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...
SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...
announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study ...
United States VMAT2 Inhibitors Market report provides comprehensive data and information about the market, which will help you grow your business and increase return on investment. This market ...
Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback